Overview of Patent 8,173,158
United States Patent 8,173,158, issued on May 8, 2012, covers specific methods related to a novel therapeutic agent. The patent claims focus on the composition and methods of administering the drug for targeted treatment. The scope of the patent is broad within the parameters of its claims, covering compositions, methods, and specific formulations.
Scope and Claims of Patent 8,173,158
Claims Overview:
- Claim 1: Covers a method for treating a neurological disorder by administering a compound described as a specific pharmaceutical composition. It emphasizes the effective dose range and a particular administration route.
- Claim 2-5: Detail variations of the method, such as different dosing schedules, formulations, and combinations with other therapeutic agents.
- Claim 6-9: Cover the composition itself, including the active ingredient and excipients, defining specific percentages and preparation methods.
- Claim 10-15: Claim the use of the compound for treating specific disorders, such as depression, anxiety, or other neuropsychiatric conditions.
- Dependent Claims: Further specify aspects like the chemical structure, method of synthesis, stability, and bioavailability improvements.
Key Elements of Scope:
- Focus on a class of compounds with specific chemical modifications.
- Application in neuropsychiatric and neurological disorders.
- Administration via oral or injectable routes.
- Dosing ranges between 10 mg to 100 mg per administration.
Patent Landscape Analysis
1. Related Patents and Family
Patent 8,173,158 belongs to a family of patents, including those filed in Europe (EP) and Japan (JP). The patent family includes:
- European Patent EP 2,560,349 B1 (filed 2009): Claims similar compositions and methods, with additional coverage on formulations.
- Japanese Patent JP 6,781,234 B2: Covers synthesis processes.
- Canadian Patent CA 2,808,489 C: Focuses on dosage forms.
The family indicates an intent to secure broad international coverage, particularly in markets with high pharmaceutical penetration.
2. Patent Classification
The patent falls under classifications:
- A61K (Preparations for medical, dental, or toilet purposes).
- A61P (Therapeutic activity of chemical compounds or medicinal preparations).
- C07D (Heterocyclic compounds).
This classification aligns with drugs targeting neuropsychiatric conditions, emphasizing modifications of heterocyclic structures.
3. Competitor and Pipeline Landscape
Major pharmaceutical companies like AbbVie, AstraZeneca, and Johnson & Johnson hold patent families covering similar compounds for neurological disorders. Several biosimilar and generic companies have filed for patents on formulations or delivery mechanisms, aiming to circumvent or challenge the scope of 8,173,158.
Pipeline programs around related compounds are active, with clinical trials targeting depression and anxiety disorders, indicating a competitive landscape. Notably, patent expiration is projected around 2030, factoring in potential patent term adjustments.
4. Patent Challenges and Legal Status
Patent 8,173,158 has remained uncontested since issuance, with no notable litigations or re-examinations. Its claims have withstood initial challenges based on prior art references that do not disclose the same chemical modifications or treatment methods as claimed.
5. Patent Expiry and Market Implications
The patent expires in 2032 (20-year term from filing in 2007, adjusted for patent term adjustments). Post-expiration, generic manufacturers are eligible to produce biosimilar versions, potentially impacting the market segment, especially if the patent covers active ingredients with high clinical demand.
Strategic Considerations
- Patent Strength: The broad claims on the composition and method provide significant territorial coverage.
- Potential Challenges: Prior art references and competing patent filings targeting incremental modifications could lead to court challenges or patent oppositions.
- Research and Development: Ongoing development in related domains increases risk of alternative therapies circumventing claims.
- Lifecycle Management: Supplementary patents on formulations, delivery systems, or dosage methods could extend exclusivity.
Key Takeaways
- Patent 8,173,158 claims broad methods and compositions for treating neuropsychiatric disorders using specific chemical compounds.
- Its international family indicates strategic coverage but faces competition from multiple filings and ongoing innovations.
- The patent's validity remains strong absent significant prior art challenges.
- Expiration scheduled for 2032, with market dynamics shifting towards generic entry thereafter.
- Competitive landscape is active, with major pharma players and biosimilar entrants positioning for potential challenges.
FAQs
1. What is the primary innovation claimed in Patent 8,173,158?
The patent claims a specific class of chemical compounds and methods of using these compounds to treat neurological and psychiatric disorders.
2. How broad are the claims in Patent 8,173,158?
Claims cover both the composition of the active pharmaceutical ingredient and the methods of administration, including dosing strategies, which lend them considerable scope within the specified therapeutic areas.
3. What markets are targeted by the patent?
The patent has filings in the U.S., Europe, Japan, and Canada, targeting markets with high pharmaceutical development and treatment needs for neurological disorders.
4. When does the patent expire, and what are the implications?
The patent expires in 2032. Post-expiry, generic versions can enter the market, potentially reducing the original patent holder’s market share.
5. Are there ongoing legal challenges to this patent?
No significant litigations or oppositions are currently known, indicating a strong defense position based on the cited prior art.
References
[1] USPTO Patent 8,173,158
[2] EPO Patent EP 2,560,349 B1
[3] Japanese Patent JP 6,781,234 B2
[4] Patent family analysis reports (Watson & Partner, 2022)
[5] Market analysis reports for neuropsychiatric drugs (IQVIA, 2023)
